Novavax, Inc. (NasdaqGS: NVAX)
Health Care · Biotechnology · US
$12.55
-1.61% today · +48.4% 1Y
Novavax, Inc. (NasdaqGS: NVAX) operates in the Biotechnology industry within the Health Care sector. The company is valued at $2.10B and employs 749 people.
Over the last twelve months the share price has gained 48.4%, trading between 6.20 and 13.39.
Tweenvest scores Novavax, Inc. across four factors: quality 42/100, value 43/100, growth 100/100. Its strongest factor is growth.
NVAX price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $2.10B
- Revenue (TTM)
- $413.80M
- P/E
- —
- EPS
- -1.52
- Dividend yield
- —
- Beta (5Y)
- 2.43
- 52-week high
- $13.39
- 52-week low
- $6.20
- Avg volume (3M)
- —
- Shares outstanding
- 164.95M
- Employees
- 749
- Next earnings
- —
About Novavax, Inc.
Novavax, Inc. is a biotechnology firm dedicated to discovering, developing, and commercializing vaccines aimed at preventing serious infectious diseases and addressing critical health needs. The company's diverse pipeline includes NVX-CoV2373, a coronavirus vaccine candidate currently undergoing two Phase III trials, one Phase IIb, and one Phase I/II trial. Also featured is NanoFlu, a nanoparticle-based seasonal quadrivalent influenza vaccine in Phase 3 clinical trials. Furthermore, Novavax is advancing ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine, which is in Phase II clinical trials for adults aged 60 and older, and in Phase I for pediatric use. The company holds a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of its COVID-19 vaccine candidate, NVX-CoV2373. Established in 1987, Novavax, Inc. is headquartered in Gaithersburg, Maryland.
- ISIN
- US6700024010
- Founded
- 1987
- Listed since
- Dec 5, 1995
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| SK bioscience Co.,Ltd.KOSE: A302440 | $2.13B | ₩36,750.00 | +0.68% |
| Anhui Anke Biotechnology (Group) Co., Ltd.SZSE: 300009 | $2.12B | CN¥8.53 | +1.79% |
| Viridian Therapeutics, Inc.NasdaqCM: VRDN | $2.11B | $18.42 | -1.29% |
| Duality Biotherapeutics, Inc.SEHK: 9606 | $2.11B | HK$182.70 | -6.64% |
| Mineralys Therapeutics, Inc.NasdaqGS: MLYS | $2.07B | $22.31 | -4.54% |
| AlvotechNasdaqGM: ALVO | $2.06B | $5.52 | -4.58% |
| Vericel CorporationNasdaqGM: VCEL | $2.05B | $40.28 | +0.45% |
| Nanjing Vazyme Biotech Co., LtdSHSE: 688105 | $2.05B | CN¥26.60 | -2.35% |
Figures last refreshed Oct 11, 2026.